| Research Code | Therapeutic Area | Indication | Development Region | Pre-Clinical | Phase I | Phase II | Phase III | NDA | Market | More |
|---|---|---|---|---|---|---|---|---|---|---|
|
ON101
|
Dermatology | Diabetic Foot Ulcer |
1. Taiwan, Macau, Singapore, Malaysia, China & Indonesia
|
|
|
|
|
|
|
|
|
2.Southeast Asia
|
|
|
|
|
|
|||||
|
FB825
|
Dermatology, Immunology | Atopic Dermatitis, Allergic Asthma |
1. Taiwan
|
|
|
|
||||
|
2. US / Taiwan(SC formulation)
|
|
|
|
|||||||
|
FB704A
|
Immunology | Severe Asthma |
Taiwan
|
|
|
|
||||
|
SNS812
|
Infection | Pan-COVID |
US
|
|
|
|
||||
|
SNS851
|
Metabolism | Weight loss, Metabolism diseases |
Taiwan
|
|
